Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Paul McNally"'
Publikováno v:
Clinics in Chest Medicine. 43:677-695
Based on the cystic fibrosis transmembrane conductance regulator (CFTR) genotype, approximately 90% of people with cystic fibrosis (CF) are candidates for highly effective modulator therapy (HEMT). Clinical trials conducted over the last 11 years hav
Autor:
Anne Trappe, Navya Lakkappa, Suzanne Carter, Eugene Dillon, Kieran Wynne, Edward McKone, Paul McNally, Judith A Coppinger
Publikováno v:
Journal of Cystic Fibrosis.
Autor:
Kevin J. O'Sullivan, Aidan G. O'Sullivan, Tjaša Kermavnar, Paul McNally, Colum P. Dunne, Barry Linnane, Leonard W. O'Sullivan
Publikováno v:
Annals of 3D Printed Medicine. 9:100091
Autor:
Gerard Higgins, Isabelle Sermet-Gaudelus, Paul McNally, Monika Hollenhorst, Ahmad Moukachar, Aurélie Hatton, Coral Fustero-Torre, Valerie Urbach, Fiona C. Ringholz, Brian J. Harvey, Ali Sassi
Publikováno v:
Journal of Cystic Fibrosis
Journal of Cystic Fibrosis, Elsevier, 2018, 17 (5), pp.607-615. ⟨10.1016/j.jcf.2017.11.017⟩
Journal of Cystic Fibrosis, Elsevier, 2018, 17 (5), pp.607-615. ⟨10.1016/j.jcf.2017.11.017⟩
Background Cystic Fibrosis (CF) lung disease is characterised by dysregulated ion transport that promotes chronic bacterial infection and inflammation. The impact of the specialised pro-resolution mediator resolvin D1 (RvD1) on airway surface liquid
Autor:
André Schultz, Shivanthan Shanthikumar, Paul McNally, Charles R. Esther, Sarath Ranganathan, Richard C. Boucher, Stephen M. Stick
Publikováno v:
Journal of Cystic Fibrosis. 20:S273
Autor:
Jane C. Davies, A. Fleming, M. Williamson, C. Zagoya, Barry Linnane, Des W. Cox, Edward F. McKone, Paul McNally, Basil Elnazir, Jochen G. Mainz
Publikováno v:
Journal of Cystic Fibrosis. 20:S267
Autor:
Jane C. Davies, M. Kemner Vandercorput, M. Williamson, Laura Kirwan, Barry Linnane, Harm A.W.M. Tiddens, Paul McNally, Clare Saunders, Basil Elnazir, Christopher Short, Des W. Cox
Publikováno v:
Journal of Cystic Fibrosis. 20:S264
Autor:
A.J.M. Reid, H.A.W.M. Tiddens, Barry Linnane, M. Williamson, Basil Elnazir, Jane C. Davies, Alexandra L. Quittner, Paul McNally, Felix Ratjen, Billy Bourke, Damian G. Downey, A. Fleming, Abaigeal D. Jackson, Edward F. McKone, Des W. Cox, Jochen G. Mainz
Publikováno v:
Journal of Cystic Fibrosis. 20:S51
Background: Real-world, post-approval studies contribute significantly to the evidence surrounding the impact of new treatments, including CFTR modulators, but can be complex undertakings. Elexacaftor-tezacaftor-ivacaftor (ETI) was approved by EMA so
Autor:
Donna M. Small, Rebecca J. Ingram, Nicolas Camper, Joseph Elborn, Arlene Glasgow, Fionnuala Lundy, Derek J. Quinn, D. McLean, Megan Osbourn, Clifford C. Taggart, Sinéad Weldon, Paul McNally
Publikováno v:
Camper, N, Glasgow, A M A, Osbourn, M, Quinn, D J, Small, D M, McLean, D T, Lundy, F T, Elborn, J S, McNally, P, Ingram, R J, Weldon, S & Taggart, C C 2016, ' A Secretory Leukocyte Protease Inhibitor Variant with Improved Activity against Lung Infection ', Mucosal immunology, vol. 9, no. 3, pp. 669-676 . https://doi.org/10.1038/mi.2015.90
Secretory leukocyte protease inhibitor (SLPI) is an important respiratory tract host defense protein, which is proteolytically inactivated by excessive neutrophil elastase (NE) during chronic Pseudomonas infection in the cystic fibrosis (CF) lung. We
Publikováno v:
Journal of Cystic Fibrosis. 19:S101